Literature DB >> 25784270

[Diagnostics of nonmuscle-invasive urothelial cell carcinoma of the bladder].

S Tschirdewahn1, F Vom Dorp.   

Abstract

Cystoscopy and transurethral resection in combination with urinary cytology are integral parts of the diagnosis and therapy of urothelial cell carcinoma of the bladder. Given the fact that low grade bladder cancer has high recurrence and extremely low progression rates, the benefit for additional diagnostics needs to be further evaluated. In high grade tumors, early and accurate diagnosis is of high importance. Fluorescence cystoscopy and narrow band imaging are procedures to increase the detection rate. This article provides an overview of the current value of these two procedures.

Entities:  

Mesh:

Year:  2015        PMID: 25784270     DOI: 10.1007/s00120-015-3772-9

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  10 in total

1.  Watchful waiting policy in recurrent Ta G1 bladder tumors.

Authors:  Ofer N Gofrit; Dov Pode; Adi Lazar; Ran Katz; Amos Shapiro
Journal:  Eur Urol       Date:  2006-01-06       Impact factor: 20.096

2.  Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology.

Authors:  Yann Neuzillet; Charlotte Methorst; Marc Schneider; Thierry Lebret; Mathieu Rouanne; Camelia Radulescu; Vincent Molinie; Jean-François Dreyfus; Veronique Pelcat; Henry Botto
Journal:  Urol Oncol       Date:  2014-07-09       Impact factor: 3.498

3.  Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy : A multicenter randomized, double-blind, placebo-controlled trial.

Authors:  Arnulf Stenzl; Hannes Penkoff; Elfriede Dajc-Sommerer; Andreas Zumbraegel; Lorenz Hoeltl; Michael Scholz; Claus Riedl; Josef Bugelnig; Alfred Hobisch; Maximilian Burger; Gregor Mikuz; Uwe Pichlmeier
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

4.  Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer.

Authors:  Evelyne C C Cauberg; Sarah Kloen; Mike Visser; Jean J M C H de la Rosette; Marko Babjuk; Viktor Soukup; Michael Pesl; Jaroslava Duskova; Theo M de Reijke
Journal:  Urology       Date:  2010-03-12       Impact factor: 2.649

5.  Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.

Authors:  Arnulf Stenzl; Maximilian Burger; Yves Fradet; Lance A Mynderse; Mark S Soloway; J Alfred Witjes; Martin Kriegmair; Alexander Karl; Yu Shen; H Barton Grossman
Journal:  J Urol       Date:  2010-09-17       Impact factor: 7.450

6.  [Urothelial carcinoma of the bladder: evaluation by combined endoscopy and urine cytology: is incontrovertible assessment possible?].

Authors:  J Hess; S Tschirdewahn; T Szarvas; R Rossi; H Rübben; F Vom Dorp
Journal:  Urologe A       Date:  2011-06       Impact factor: 0.639

7.  Does cystoscopy correlate with the histology of recurrent papillary tumours of the bladder?

Authors:  H W Herr
Journal:  BJU Int       Date:  2001-11       Impact factor: 5.588

8.  Expectant management of small, recurrent, noninvasive papillary bladder tumors.

Authors:  Mark S Soloway; Darren S Bruck; Sandy S Kim
Journal:  J Urol       Date:  2003-08       Impact factor: 7.450

Review 9.  Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.

Authors:  Maximilian Burger; H Barton Grossman; Michael Droller; Joerg Schmidbauer; Gregers Hermann; Octavian Drăgoescu; Eleanor Ray; Yves Fradet; Alexander Karl; Juan Pablo Burgués; J Alfred Witjes; Arnulf Stenzl; Patrice Jichlinski; Dieter Jocham
Journal:  Eur Urol       Date:  2013-04-08       Impact factor: 20.096

10.  Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study.

Authors:  Martin C Schumacher; Sten Holmäng; Thomas Davidsson; Bengt Friedrich; Jörgen Pedersen; N Peter Wiklund
Journal:  Eur Urol       Date:  2009-11-06       Impact factor: 20.096

  10 in total
  1 in total

1.  Clinicopathological significance of claspin overexpression and its efficacy as a novel biomarker for the diagnosis of urothelial carcinoma.

Authors:  Go Kobayashi; Tetsutaro Hayashi; Kazuhiro Sentani; Takashi Babasaki; Yohei Sekino; Shogo Inoue; Naohiro Uraoka; Masanori Hanamoto; Hiroyuki Nose; Jun Teishima; Naohide Oue; Akio Matsubara; Naomi Sasaki; Wataru Yasui
Journal:  Virchows Arch       Date:  2021-11-29       Impact factor: 4.535

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.